Crescent Biopharma, INC. (CBIO) — 10-Q Filings

10-Q Filings (6)

• Crescent Biopharma's Cash Surges Post-Financing Amidst Deepening Losses — Nov 6, 2025 Risk: high
  Crescent Biopharma, Inc. (CBIO) reported a significant increase in cash and cash equivalents to $133.265 million as of September 30, 2025, up from $34.766 milli
• Crescent Biopharma Reports Zero Revenue, $20.1M Net Loss Amid Pipeline Development — Jul 31, 2025 Risk: high
  CRESCENT BIOPHARMA, INC. (CBIO) reported no revenue for the three and six months ended June 30, 2025, consistent with its pre-commercial stage. The company incu
• GlycoMimetics Q1 2025 10-Q Filed — May 14, 2025 Risk: medium
  GlycoMimetics Inc. filed its 10-Q for the period ending March 31, 2025. The company reported total assets of $64.5 million and total liabilities of $64.4 millio
• GlycoMimetics Q3 2024 Update: Equity Changes Detailed — Nov 13, 2024 Risk: medium
  GlycoMimetics Inc. reported its third quarter 2024 results on November 13, 2024. The company's financial statements for the period ending September 30, 2024, sh
• GlycoMimetics Q2 2024 Financials: Capital Structure Insights — Aug 8, 2024 Risk: medium
  GlycoMimetics Inc. reported its second quarter 2024 financial results on August 8, 2024. The company's financial statements for the period ending June 30, 2024,
• GlycoMimetics Inc. Files 10-Q for Period Ending March 31, 2024 — May 9, 2024 Risk: low
  GLYCOMIMETICS INC (CBIO) filed a Quarterly Report (10-Q) with the SEC on May 9, 2024. GlycoMimetics Inc. filed a 10-Q report for the period ending March 31, 202

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX